How to Navigate Ecosystem Connect NEWDistinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats
A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solution for Injection (TLX101-Tx) Plus Lomustine Versus Lomustine Alone in Patients With Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IPAX BrIGHT [IPAX-3])
Description:
A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solution for Injection (TLX101-Tx) Plus Lomustine Versus Lomustine Alone in Patients With Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IPAX BrIGHT [IPAX-3])
Sponsor:
Telix PharmaceuticalsContacts:
Neil Smith (Clinical Project Manager)neil.smith@telixpharma.com
Samuel Park (Clinical Project Manager)samuel.park@telixpharma.com
Government Study Link:
NCT07100730 - Click here to see study onClinicalTrials.gov
TLX101 aka 131I-iodofalan
Isotope(s):
Target(s):
- L-type amino acid transporter 1 (LAT1)
Ligand: Small Molecules
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations
Australia 🇦🇺
Gold Coast University Hospital
Queensland, Australia
